Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type% u7 t! f5 h5 P$ K, U
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * w- M0 e4 M h5 b
+ Author Affiliations
& P( M7 u8 W' d) N( g ]* H+ }: x/ L; c p q! L9 K; a
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 2 |1 ^+ B7 _6 ?0 ?
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) B, f- x/ R* t4 {) G0 n: I
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 B3 }; |! I& e0 j+ K4 |' h! ]) b' E
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
Q& G9 Y' C7 C' D5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
. b0 d5 |( f: E* x6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
& N& Z0 U) Z/ u6 Q( ]' _7Kinki University School of Medicine, Osaka 589-8511, Japan
7 G# o* o5 ^: B* n- J8Izumi Municipal Hospital, Osaka 594-0071, Japan
5 ^) J/ @# P/ ]0 A6 _9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan , ^" E' \* z' I$ P6 X
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ! I9 o; i a e. Y+ n, M4 H1 Y
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
1 n/ n3 p- e/ p; |/ E$ l. n
5 l* ]+ c" G: M! {8 Y, u |